Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
What’s Trending in Microbials: From Niche Biologicals to Mainstream Crop Inputs
4+ hour, 53+ min ago (524+ words) Although the microbials market is somewhat segmented, in row crops such as corn and soybean, inoculants and biological seed treatments lead global adoption, particularly in Brazil and the U.S. In Brazil especially, large-scale soybean production has normalized the use of microbial…...
Cleveland wound-care startup nears FDA approval after raising $3.4M
2+ hour, 38+ min ago (40+ words) Crain's Cleveland Business Cleveland wound-care startup nears FDA approval after raising $3.4M Both firms at the top of the list posted revenue declines for 2025 as some big projects wrapped up....
Kura Oncology: 'Strong Buy' Ziftomenib AML Expansions Could Boost KOMZIFTI's Prospects
3+ hour, 51+ min ago (114+ words) Kura Oncology: 'Strong Buy': Ziftomenib AML Expansions With Different Regimens Could Boost KOMZIFTI's Prospects Seeking Alpha - Kura Oncology maintains a “Strong Buy” rating, driven by KOMZIFTI's FDA approval and robust early commercial performance in relapsed/refractory NPM1-mutated AML. - The company…...
Novonesis Expands U.S. Workforce Development Efforts to Build the Next Generation of Biomanufacturing Talent | Taiwan News | Aug. 26, 2026 20:00
10+ hour, 8+ min ago (167+ words) Building the talent pipeline across the U.S. The Nebraska partnership is part of a broader Novonesis approach to building biotechnology talent by engaging students at multiple points in their education and career journeys. As Novonesis continues to grow its U.S. operations and…...
Cellares rebukes Bristol Myers' criticism of its cell therapy technology
4+ hour, 28+ min ago (101+ words) Cellares rebukes Bristol Myers’ criticism of its cell therapy technology Endpoints News Cellares rebukes Bristol Myers' criticism of its cell therapy technology Cell therapy manu…...
Pharmaceutical Executive Daily: Haisco Licenses Preclinical Immunology Asset to Sentivera
just now (497+ words) Haisco Licenses Preclinical Immunology Asset to Sentivera | PharmExec Pharmaceutical Executive Pharmaceutical Executive Daily: Haisco Licenses Preclinical Immunology Asset to Sentivera A new Eli Lilly study links Zepbound to lower healthcare costs in older adults with obesity, Biohaven and Haisco strike…...
HEART: Advanced toward clinical readiness with new patents, funding, and improved financial stability
6+ hour, 7+ min ago (70+ words) TradingView HEART: Advanced toward clinical readiness with new patents, funding, and improved financial stability Key milestones included ethical approval for chronic studies, new patents, and a SEK 49 million rights issue. Losses widened year-over-year, but cash position and equity/assets ratio…...
Biohaven strikes $795M deal for commercial partner in epilepsy
5+ hour, 1+ min ago (78+ words) Endpoints News Biohaven strikes $795M deal for commercial partner in epilepsy Biohaven has found a commercial partner for its late-stage epilepsy drug. South Korea-based SK Biopharmaceuti…...
The buyers' wishlist: What makes a life sciences deal stack up?
21+ hour, 21+ min ago (101+ words) Life Sciences IP Review - The buyers' wishlist: What makes a life sciences deal stack up? While promising science draws in buyers, intellectual property determines the price, terms, and viability of an agreement. LSIPR digs into what investors are looking for…...
GSK's ViiV Healthcare Says US FDA Approves Tivicay PD for Pediatric HIV Patients
6+ hour, 38+ min ago (44+ words) Published on 08/26/2026 at 11:30 am EDT A No to BMS can open doors for a Yes to GSK August 12, 2026 at 08:55 am EDT Goldman Sachs still cautious about GSK GSK: shareholders urge company to step up reinvention...